Drugs / BBM-D101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06641895 | Jul 2024 → Jul 2026 overdue | Duchenne muscular dystrophy | Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07058662 | Jul 2025 → Jun 2027 expected | Duchenne muscular dystrophy | Belief BioMed (Beijing) Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBM-D101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06641895 ↗ |
| Action | Restore | “Therapeutic protein could mediate the dystrophin-associated protein complex to prevent muscular dystrophy and to rescue the function of muscle.” NCT07058662 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “BBM-D101 is a recombinant adeno-associated virus vector-based gene therapy for DMD treatment.” NCT06641895 ↗ |
| Route | Intravenous | “single intravenous (IV) infusion” NCT06641895 ↗ |